ONO AE 248

Drug Profile

ONO AE 248

Latest Information Update: 22 Aug 2002

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Class Anti-ischaemics; Prostaglandins
  • Mechanism of Action Potassium channel agonists; Prostaglandin E3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Reperfusion injury

Most Recent Events

  • 25 Jun 1998 New profile
  • 25 Jun 1998 Preclinical development for Reperfusion injury in Japan (Unknown route)
  • 25 Jun 1998 Preclinical development for Reperfusion injury in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top